Zeria Pharmaceutical Co., Ltd.

TSE:4559 Voorraadrapport

Marktkapitalisatie: JP¥101.6b

Zeria Pharmaceutical Toekomstige groei

Future criteriumcontroles 2/6

Zeria Pharmaceutical is forecast to grow earnings and revenue by 7.7% and 7.8% per annum respectively. EPS is expected to grow by 7.7% per annum. Return on equity is forecast to be 10.6% in 3 years.

Belangrijke informatie

7.7%

Groei van de winst

7.7%

Groei van de winst per aandeel

Pharmaceuticals winstgroei11.9%
Inkomstengroei7.8%
Toekomstig rendement op eigen vermogen10.6%
Dekking van analisten

Low

Laatst bijgewerkt10 Jul 2024

Recente toekomstige groei-updates

Recent updates

Zeria Pharmaceutical's (TSE:4559) Earnings Are Of Questionable Quality

May 21
Zeria Pharmaceutical's (TSE:4559) Earnings Are Of Questionable Quality

Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥22.00

Mar 15
Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥22.00

Winst- en omzetgroeiprognoses

TSE:4559 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (JPY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/202797,80010,70012,450N/A1
3/31/202690,0009,20011,150N/A1
3/31/202583,5008,00010,300N/A1
6/30/202478,8769,028N/AN/AN/A
3/31/202475,7257,7318,28512,183N/A
12/31/202374,5738,638N/AN/AN/A
9/30/202371,3497,5938,91312,789N/A
6/30/202370,3826,509N/AN/AN/A
3/31/202368,3836,19510,50013,157N/A
12/31/202266,1575,898N/AN/AN/A
9/30/202264,6385,8449,26211,171N/A
6/30/202262,2895,154N/AN/AN/A
3/31/202259,5323,9617,5308,950N/A
12/31/202158,1723,476N/AN/AN/A
9/30/202157,2393,846-5,9068,796N/A
6/30/202155,6593,553N/AN/AN/A
3/31/202155,4423,119-9,2386,894N/A
12/31/202056,4974,272N/AN/AN/A
9/30/202056,9183,0833,4636,125N/A
6/30/202058,6442,753N/AN/AN/A
3/31/202060,4262,9255,9787,251N/A
12/31/201960,9192,893N/AN/AN/A
9/30/201961,6652,4044,8075,975N/A
6/30/201961,6852,356N/AN/AN/A
3/31/201961,8313,4543,9835,500N/A
12/31/201862,1393,102N/AN/AN/A
9/30/201862,6394,3095,7997,265N/A
6/30/201863,8575,744N/AN/AN/A
3/31/201864,5684,157N/A8,821N/A
12/31/201765,4504,626N/AN/AN/A
9/30/201764,9483,666N/A6,508N/A
6/30/201764,3312,873N/AN/AN/A
3/31/201764,8493,544N/A7,238N/A
12/31/201664,4643,051N/AN/AN/A
9/30/201664,4453,903N/A9,799N/A
6/30/201664,2383,950N/AN/AN/A
3/31/201662,4753,513N/A5,694N/A
12/31/201562,2842,732N/AN/AN/A
9/30/201561,2192,058N/A4,066N/A
6/30/201561,0222,400N/AN/AN/A
3/31/201561,0122,557N/A653N/A
12/31/201461,0053,866N/AN/AN/A
9/30/201462,0234,056N/A1,213N/A
6/30/201461,3713,890N/AN/AN/A
3/31/201461,9965,277N/A6,573N/A
12/31/201359,7915,276N/AN/AN/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 4559's forecast earnings growth (7.7% per year) is above the savings rate (0.3%).

Winst versus markt: 4559's earnings (7.7% per year) are forecast to grow slower than the JP market (8.9% per year).

Hoge groeiwinsten: 4559's earnings are forecast to grow, but not significantly.

Omzet versus markt: 4559's revenue (7.8% per year) is forecast to grow faster than the JP market (4.2% per year).

Hoge groei-inkomsten: 4559's revenue (7.8% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: 4559's Return on Equity is forecast to be low in 3 years time (10.6%).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y